Interplay of leucocyte-platelet complexes and clinical response to eltrombopag in immune thrombocytopenia patients.
autoimmune disease
cellular immunology
immunology
immunophenotyping
platelet immunology
thrombocytopenia
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
26 Sep 2024
26 Sep 2024
Historique:
received:
16
05
2024
accepted:
10
09
2024
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
27
9
2024
Statut:
aheadofprint
Résumé
Eltrombopag (ELT) is a thrombopoietin-receptor agonist that stimulates platelet (PLT) production in patients with primary immune thrombocytopenia (ITP). One potential mechanism of ELT is modulating the inflammatory response by increasing PLTs binding to leucocytes. This study examined the effect of ELT on leucocyte-PLTs complexes in 38 ITP patients. Patients, predominantly females with a mean age of 59 years, underwent treatments like corticosteroids, intravenous immunoglobulin and splenectomy. Compared to healthy donors, ITP patients exhibited lower percentages of lymphocyte with bound PLTs, but similar monocyte- or neutrophil with bound PLTs. ELT treatment increased PLTs counts and all types of leucocyte with bound PLTs. Network analysis showed dynamic changes in leucocyte with bound PLTs relationships due to ELT. Machine learning indicated that higher percentages of monocytes with bound PLTs were linked to a better clinical response to ELT. A possible mechanism was an increased IL-10 production in monocytes with bound PLTs from responder patients. This study provides insights into the immunological changes in ITP patients undergoing ELT and suggests potential predictive biomarkers for treatment response and disease monitoring.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Novartis
ID : IIBSP-PTI-2018-65
Informations de copyright
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
Références
González‐López TJ, Provan D, Bárez A, Bernardo‐Gutiérrez A, Bernat S, Martínez‐Carballeira D, et al. Primary and secondary immune thrombocytopenia (ITP): time for a rethink. Blood Rev. 2023;61:101112.
Tinazzi E, Osti N, Beri R, Argentino G, Veneri D, Dima F, et al. Pathogenesis of immune thrombocytopenia in common variable immunodeficiency. Autoimmun Rev. 2020;19:102616.
Talaat RM, Elmaghraby AM, Barakat SS, El‐Shahat M. Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP). Clin Exp Immunol. 2014;176:291–300.
Andreescu M. The link between immune thrombocytopenia and the cytokine profile: a bridge to new therapeutical targets. Front Hematol. 2023;1–12.
Swinkels M, Rijkers M, Voorberg J, Vidarsson G, Leebeek FWG, Jansen AJG. Emerging concepts in immune thrombocytopenia. Front Immunol. 2018;9:880.
Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine. 2022;76:103820.
Liu B, Zhao H, Poon MC, Han Z, Gu D, Xu M, et al. Abnormality of CD4+CD25+ regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol. 2007;78:139–143.
Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood. 2020;135:472–490.
Tarantini F, Cumbo C, Anelli L, Zagaria A, Conserva MR, Redavid I, et al. Exploring the potential of eltrombopag: room for more? Front Pharmacol. 2022;13:906036.
Rodeghiero F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. Br J Haematol. 2018;181:183–195.
Guillet S, Crickx E, Azzaoui I, Chappert P, Boutin E, Viallard JF, et al. Prolonged response after TPO‐RA discontinuation in primary ITP: results of a prospective multicenter study. Blood. 2023;141:2867–2877.
Cooper N, Ghanima W, Vianelli N, Valcárcel D, Yavaşoğlu İ, Melikyan A, et al. Sustained response off‐treatment in eltrombopag‐treated adult patients with ITP who are refractory or relapsed after first‐line steroids: primary, final, and ad‐hoc analyses of the phase II TAPER trial. Am J Hematol. 2024;99:57–67.
Di Paola A, Palumbo G, Tortora C, Argenziano M, Catanoso M, Di Leva C, et al. Eltrombopag in paediatric immune thrombocytopenia: iron metabolism modulation in mesenchymal stromal cells. Br J Haematol. 2021;197:110–119.
Sayed AA, Malik A, Ayoola G, Lucchini E, Candrianita S, Tan MH, et al. Eltrombopag: more than just a thrombopoietin receptor agonist (TPO‐RA) in immune thrombocytopenia (ITP). Blood. 2019;134:2364.
Lam FW, Vijayan KV, Rumbaut RE. Platelets and their interactions with other immune cells. Compr Physiol. 2015;5:1265–1280.
Zamora C, Toniolo E, Diaz‐Torné C, Cantó E, Magallares B, Ortiz MA, et al. Association of platelet binding to lymphocytes with B cell abnormalities and clinical manifestations in systemic lupus erythematosus. Mediat Inflamm. 2019;2019:2473164.
Zamora C, Canto E, Nieto JC, Garcia‐Planella E, Gordillo J, Ortiz MA, et al. Inverse association between circulating monocyte‐platelet complexes and inflammation in ulcerative colitis patients. Inflamm Bowel Dis. 2018;24:818–828.
Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829–3866.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–2393.
Ziegler‐Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116:e74–e80.
Teraz‐Orosz A, Cooper N, Crawley JTB, Salles‐Crawley II. Detection of anti‐platelet antibodies in immune thrombocytopenia by flow cytometry. Br J Haematol. 2019;184:844–847.
Mulet M, Osuna‐Gómez R, Zamora C, Artesero I, Arús M, Vera‐Artazcoz P, et al. Dysregulated neutrophil extracellular traps formation in sepsis. Immunology. 2023;170:374–387.
Anguera G, Mulet M, Zamora C, Osuna‐Gómez R, Barba A, Sullivan I, et al. Potential role of circulating PD‐L1+ leukocytes as a predictor of response to anti‐PD‐(L)1 therapy in NSCLC patients. Biomedicine. 2024;12:958–975.
Gerrits AJ, Frelinger AL III, Michelson AD. Whole blood analysis of leukocyte‐platelet aggregates. Curr Protoc Cytom. 2016;78:6.15.1–6.15.10.
Kawabe T, Matsushima M, Hashimoto N, Imaizumi K, Hasegawa Y. CD40/CD40 ligand interactions in immune responses and pulmonary immunity. Nagoya J Med Sci. 2011;73:69–78.
An G, Wang H, Tang R, Yago T, McDaniel JM, McGee S, et al. P‐selectin glycoprotein ligand‐1 is highly expressed on Ly‐6Chi monocytes and a major determinant for Ly‐6Chi monocyte recruitment to sites of atherosclerosis in mice. Circulation. 2008;117:3227–3237.
Ley K, Kansas GS. Selectins in T‐cell recruitment to non‐lymphoid tissues and sites of inflammation. Nat Rev Immunol. 2004;4:325–335.
Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012;119:4066–4072.
Allen N, Barrett TJ, Guo Y, Nardi M, Ramkhelawon B, Rockman CB, et al. Circulating monocyte‐platelet aggregates are a robust marker of platelet activity in cardiovascular disease. Atherosclerosis. 2019;282:11–18.
Barrett TJ, Schlegel M, Zhou F, Gorenchtein M, Bolstorff J, Moore KJ, et al. Platelet regulation of myeloid suppressor of cytokine signaling 3 accelerates atherosclerosis. Sci Transl Med. 2019;11:1–15.
Zhong H, Bao W, Li X, Miller A, Seery C, Haq N, et al. CD16+ monocytes control T‐cell subset development in immune thrombocytopenia. Blood. 2012;120:3326–3335.
Liu Q, Liu Y. Role of IL‐10 and IL‐22 cytokines in patients with primary immune thrombocytopenia and their clinical significance. J Clin Lab Anal. 2022;36:e24573.
Li F, Ji L, Wang W, Hua F, Zhan Y, Zou S, et al. Insufficient secretion of IL‐10 by Tregs compromised its control on over‐activated CD4+ T effector cells in newly diagnosed adult immune thrombocytopenia patients. Immunol Res. 2015;61:269–280.
Yang F, Zong H, Li F, Luo S, Zhang X, Xu Y, et al. Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia. Platelets. 2022;34:2135694.
Di Paola A, Palumbo G, Merli P, Argenziano M, Tortora C, Strocchio L, et al. Effects of Eltrombopag on in vitro macrophage polarization in pediatric immune thrombocytopenia. Int J Mol Sci. 2020;22:97–109.
Saraiva M, O'Garra A. The regulation of IL‐10 production by immune cells. Nat Rev Immunol. 2010;10:170–181.
Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long‐term, open‐label EXTEND study. Blood. 2013;121:537–545.
Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte‐platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P‐selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001;104:1533–1537.